Yay, I guess


So as women living alone age, we’re going to drug them up because it’s cheaper than providing support services and higher Social Security payments?

According to a new study, women experiencing difficulty with time management, attention, organization, memory, and problem solving – often referred to as executive functions – related to menopause may find improvement with a drug already being used to treat attention deficit hyperactivity disorder (ADHD). The study led by researchers at the Perelman School of Medicine at the University of Pennsylvania is the first to show that lisdexamfetamine (LDX) improved subjective and objective measures of cognitive decline commonly experienced in menopausal women. Results of the study are published online today in the journal Psychopharmacology.

“Reports of cognitive decline, particularly in executive functions, are widespread among menopausal women,” said lead author, C. Neill Epperson, MD, professor of Psychiatry and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, and director of the Penn Center for Women’s Behavioral Wellness. “There are approximately 90 million post-menopausal women living in the US alone, and with the average age of onset occurring at 52, the great majority of those women will live in the postmenopausal state for at least one-third of their lives. Therefore, promoting healthy cognitive aging among menopausal women should be a major public health goal.”

One thought on “Yay, I guess

  1. This post-menopausal population is just too lucrative to ignore. First it was hormone replacement. I heard a gynecologist give a talk, a number of years ago, saying that all post-menopausal women should be on hormone replacement. Then it finally came out that it lead to higher rates of cancer. So that little gold mine disappeared. So now, post menopausal women are to be treated with ADHD drugs for 30-40 years. What a racket! No thanks.

Comments are closed.